Pat Fox Fulgham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pat Fox Fulgham has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Daniel B. Rukstalis
Wake Forest Baptist Medical Center, Medical Center Boulevard
2 shared publicationsR. Ernest Sosa
Veterans Administration Healthcare System, New York Harbor
2 shared publications- Tillmann Loch
Diakonnissenkrankenhaus Flensburg
2 shared publications Alexia Demitsas
Urology Clinics North Texas 8230 Walnut Hill Lane Suite 700 Dallas TX USA
1 shared publication- Alexia Demitsas1 shared publication
Angela R Clark
Urology Research & Education Foundation Dallas TX USA
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by Research Lake International Inc. in International Journal of Radiology Case Reports
- Vol. 2 (2) , 64-73
Short-Term Androgen Deprivation Therapy and 18F-flotufolastat PSMA PET/CT Imaging for Prostate Cancer Staging: A Pilot Study
Rationale: This pilot study evaluates the impact of short-term Androgen Deprivation Therapy (ADT) on the findings on 18F-flotufolastat PSMA PET/CT scan when used for staging prostate cancer prior to a Robot-Assisted Radical Prostatectomy (RARP) and bilateral Pelvic Lymph Node Dissection (PLND). Methods: Ten patients with unfavorable intermediate, high or very-high risk prostate cancer were assigned to one of two cohorts, A and B (n=5 each). Baseline serum Prostate-Specific Antigen (PSA) and testosterone were measured, followed by an 18F-flotufolastat PSMA PET/CT. All patients then underwent either 3 weeks (cohort A) or 6 weeks (cohort B) of relugolix therapy. A second PSMA PET/CT was performed immediately upon ADT completion. Quantitative and qualitative changes in PSMA PET/CT findings were analyzed. Results: All patients reached castrate levels of testosterone (<20 ng/dL) within 3 weeks of the initiation of ADT. Only 1 patient (10%) exhibited a 16.1% increase in the maximum standardized uptake value (SUVmax) of the primary intraprostatic lesion. No new clinically significant findings were detected on the post-ADT PSMA PET/CT compared to pre-ADT scans and no pre-existing findings were obscured post-ADT. No serious adverse events related to ADT were reported. Conclusion: Short-term ADT (3 and 6 weeks) did not alter PSMA PET/CT findings in a manner that would impact surgical planning or management.
- 30 December 2025
- Published by Research Lake International Inc. in International Journal of Radiology Case Reports
- Vol. 2 (2) , 64-73
Open AccessShort-Term Androgen Deprivation Therapy and 18F-flotufolastat PSMA PET/CT Imaging for Prostate Cancer Staging: A Pilot Study
Rationale: This pilot study evaluates the impact of short-term Androgen Deprivation Therapy (ADT) on the findings on 18F-flotufolastat PSMA PET/CT scan when used for staging prostate cancer prior to a Robot-Assisted Radical Prostatectomy (RARP) and bilateral Pelvic Lymph Node Dissection (PLND). Methods: Ten patients with unfavorable intermediate, high or very-high risk prostate cancer were assigned to one of two cohorts, A and B (n=5 each). Baseline serum Prostate-Specific Antigen (PSA) and testosterone were measured, followed by an 18F-flotufolastat PSMA PET/CT. All patients then underwent either 3 weeks (cohort A) or 6 weeks (cohort B) of relugolix therapy. A second PSMA PET/CT was performed immediately upon ADT completion. Quantitative and qualitative changes in PSMA PET/CT findings were analyzed. Results: All patients reached castrate levels of testosterone (<20 ng/dL) within 3 weeks of the initiation of ADT. Only 1 patient (10%) exhibited a 16.1% increase in the maximum standardized uptake value (SUVmax) of the primary intraprostatic lesion. No new clinically significant findings were detected on the post-ADT PSMA PET/CT compared to pre-ADT scans and no pre-existing findings were obscured post-ADT. No serious adverse events related to ADT were reported. Conclusion: Short-term ADT (3 and 6 weeks) did not alter PSMA PET/CT findings in a manner that would impact surgical planning or management.
- Open Access
Short-Term Androgen Deprivation Therapy and 18 F-flotufolastat PSMA PET/CT Imaging for Prostate Cancer Staging: A Pilot Study
Introduction: This pilot study evaluates the impact of short-term androgen deprivation therapy (ADT) on the findings on 18 F-flotufolastat PSMA PET/CT scan when used for staging prostate cancer prior to a robot-assisted radical prostatectomy (RARP) and bilateral pelvic lymphadenectomy (PLND). Methods: Ten patients with unfavorable intermediate, high, or very-high risk prostate cancer were assigned to one of two cohorts, A and B (n=5 each). Baseline serum prostate-specific antigen (PSA) and testosterone were measured, followed by an 18 F-flotufolastat PSMA PET/CT. All patients then underwent either 3 weeks (Cohort A) or 6 weeks (Cohort B) of relugolix therapy. A second PSMA PET/CT was performed immediately upon ADT completion. Quantitative and qualitative changes in PSMA PET/CT findings were analyzed. Results: All patients reached castrate levels of testosterone (<20 ng/dL) within 3 weeks of the initiation of ADT. Only 1 patient (10%) exhibited a 16.1% increase in the maximum standardized uptake value (SUVmax) of the primary intraprostatic lesion. No new clinically significant findings were detected on the post-ADT PSMA PET/CT compared to pre-ADT scans, and no pre-existing findings were obscured post-ADT. No serious adverse events related to ADT were reported. Discussion: Short-term ADT (3 and 6 weeks) did not alter PSMA PET/CT findings in a manner that would impact surgical planning or management.
Open AccessShort-Term Androgen Deprivation Therapy and 18 F-flotufolastat PSMA PET/CT Imaging for Prostate Cancer Staging: A Pilot Study
Introduction: This pilot study evaluates the impact of short-term androgen deprivation therapy (ADT) on the findings on 18 F-flotufolastat PSMA PET/CT scan when used for staging prostate cancer prior to a robot-assisted radical prostatectomy (RARP) and bilateral pelvic lymphadenectomy (PLND). Methods: Ten patients with unfavorable intermediate, high, or very-high risk prostate cancer were assigned to one of two cohorts, A and B (n=5 each). Baseline serum prostate-specific antigen (PSA) and testosterone were measured, followed by an 18 F-flotufolastat PSMA PET/CT. All patients then underwent either 3 weeks (Cohort A) or 6 weeks (Cohort B) of relugolix therapy. A second PSMA PET/CT was performed immediately upon ADT completion. Quantitative and qualitative changes in PSMA PET/CT findings were analyzed. Results: All patients reached castrate levels of testosterone (<20 ng/dL) within 3 weeks of the initiation of ADT. Only 1 patient (10%) exhibited a 16.1% increase in the maximum standardized uptake value (SUVmax) of the primary intraprostatic lesion. No new clinically significant findings were detected on the post-ADT PSMA PET/CT compared to pre-ADT scans, and no pre-existing findings were obscured post-ADT. No serious adverse events related to ADT were reported. Discussion: Short-term ADT (3 and 6 weeks) did not alter PSMA PET/CT findings in a manner that would impact surgical planning or management.
- Open Access
- 30 March 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 617-618
The critical and evolving role of urologist performed imaging
- 30 March 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 617-618
Open AccessThe critical and evolving role of urologist performed imaging
- 19 April 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 627-634
A template for conducting a post-graduate hands-on, urologic ultrasound course
Purpose To describe a program for post-graduate education of urologists providing urologic ultrasound services. Methods A detailed description of the evolution of an educational program developed by the American Urological Association (AUA) Office of Education for providing the knowledge and fundamental skills necessary for urologists to provide high-quality, medically appropriate urologic ultrasound examinations. The structure of the program, as well as the training of instructors and certification of attainment of the goals and skills set forth in the program, is highlighted. Specific recommendations for providing didactic instruction and managing the logistics of the hands-on training are given. Results Approximately 1700 urologists have received post-graduation instruction in the performance of urologic ultrasound in some form under the auspices of the AUA Office of Education since 1993. The hands-on training course has continued to evolve in response to feedback from the attendees and the ongoing emergence of new clinical indications for urologist-performed ultrasound. A post graduate course, including didactic instruction and hands-on skill training, continues to be in demand and fully subscribed and attended. Conclusion Instruction in the performance of diagnostic ultrasound examinations is not a formal component of many urologic residencies in the United States. Since many ultrasound procedures are being performed by practicing urologists, there is an ongoing need for post-graduate training in urologic ultrasound.
- 19 April 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 627-634
A template for conducting a post-graduate hands-on, urologic ultrasound course
Purpose To describe a program for post-graduate education of urologists providing urologic ultrasound services. Methods A detailed description of the evolution of an educational program developed by the American Urological Association (AUA) Office of Education for providing the knowledge and fundamental skills necessary for urologists to provide high-quality, medically appropriate urologic ultrasound examinations. The structure of the program, as well as the training of instructors and certification of attainment of the goals and skills set forth in the program, is highlighted. Specific recommendations for providing didactic instruction and managing the logistics of the hands-on training are given. Results Approximately 1700 urologists have received post-graduation instruction in the performance of urologic ultrasound in some form under the auspices of the AUA Office of Education since 1993. The hands-on training course has continued to evolve in response to feedback from the attendees and the ongoing emergence of new clinical indications for urologist-performed ultrasound. A post graduate course, including didactic instruction and hands-on skill training, continues to be in demand and fully subscribed and attended. Conclusion Instruction in the performance of diagnostic ultrasound examinations is not a formal component of many urologic residencies in the United States. Since many ultrasound procedures are being performed by practicing urologists, there is an ongoing need for post-graduate training in urologic ultrasound.
- 18 November 2021
- Published by Springer Nature
- p. 109-128
Prostate Biopsy: Ultrasound
- 1 October 2020
- Published by Springer Nature
- p. 31-37
Bioeffects and Safety
- 1 October 2020
- Published by Springer Nature
- p. 39-50
Maximizing Image Quality: User-Dependent Variables
- 1 October 2020
- Published by Springer Nature
- p. 39-50
Maximizing Image Quality: User-Dependent Variables